Arcturus Therapeutics is trading 9.54% higher at $10.45, with biotech-sector strength a possible factor.
- XBI rose 2.13% during the regular session, supporting a sector-led explanation.
- No clear company-specific announcement explaining the November 4 move surfaced.
- Q3 results are scheduled for November 5; the earnings preview is upcoming, not reported. A prior-week report said biotech ETFs outperformed the broader market.